Clinical Trial: Phase III Study of 608 in the Treatment of Active Ankylosing Spondylitis in Adults

U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07261644) titled 'Phase III Study of 608 in the Treatment of Active Ankylosing Spondylitis in Adults' on Nov. 21.

Brief Summary: This study will evaluate the efficacy and safety of 608 in patients with AS.

Study Start Date: Nov. 07

Study Type: INTERVENTIONAL

Condition: Ankylosing Spondylitis

Intervention: DRUG: 608 dose

608 subcutaneous (SC) injection.

DRUG: Placebo

Placebo subcutaneous (SC) injection.

Recruitment Status: RECRUITING

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Disclaimer: Curated by HT Syndication....